Baxter International (BAX)
Technical, fundamental, and sentiment analysis with recent related videos.
BAX rates Neutral overall. The fundamental read is neutral: the company passes 5 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Grey zone (Altman Z = 2.26); revenue is declining about 8.2% per year. The technical picture is bullish: price is 19.2% above the 200-day moving average; 2.1% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bearish (composite 20/100), based on 8 news articles from recent coverage.
Revenue 3-year avg -8.2%. Net income 3-year avg N/A.
Price vs 20DMA +3.3%. RSI 56.82. Bollinger state: Inside Bands.
Composite score 20/100 from the AI judge, based on 8 news items, 0 television segments, and 0 videos.
Latest Market Read
Baxter’s three badges pull in different directions. Fundamentals sit at Neutral even though revenue has averaged a -8.2 percent annual decline over the last three years, a tone that leans negative but not large enough to flip the label. Technical is Bullish: the Relative Strength Index (RSI), a momentum reading, is 56.8, the price is about 3.3 percent above its 20-day moving average, and the stock trades inside the Bollinger Bands (volatility contained), though volume is below average. Sentiment is Bearish at 20/100. Those offsets produce an Overall Neutral rating.
Recent news: Coverage is dominated by reports of an October 2026 FDA warning letter to Baxter's Round Lake injectable facility citing CGMP, GMP and QSR violations including cephalosporin segregation and aseptic-processing weaknesses, and articles link the notice to possible remediation costs and oversight. The alerts coincided with shares dropping roughly 3.8% and as much as ~5% to an intraday low near $23.97, while 13F filings show modest institutional buys from Lmcg and Sumitomo Mitsui that do not negate the regulatory-driven negative tone across multiple sources.
Latest Videos
- No qualified videos yet.